Attached files
| file | filename |
|---|---|
| EX-32 - EX-32 - CTI BIOPHARMA CORP | ctic-ex32_7.htm |
| EX-31.2 - EX-31.2 - CTI BIOPHARMA CORP | ctic-ex312_9.htm |
| EX-31.1 - EX-31.1 - CTI BIOPHARMA CORP | ctic-ex311_6.htm |
| EX-10.3 - EX-10.3 - CTI BIOPHARMA CORP | ctic-ex103_233.htm |
| 10-Q - 10-Q - CTI BIOPHARMA CORP | ctic-10q_20150630.htm |
| EX-10.1 - EX-10.1 - CTI BIOPHARMA CORP | ctic-ex101_334.htm |
Exhibit 15
August 6, 2015
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Commissioners:
We are aware that our report (which includes an explanatory paragraph as to the Company’s ability to continue as a going concern) dated August 6, 2015 on our review of interim financial information of CTI BioPharma Corp. for the three- and six-month periods ended June 30, 2015 and 2014, and included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2015, is incorporated by reference in the Registration Statements of CTI BioPharma Corp. on Forms S-3 (Nos. 333-108926, 333-134126, 333-149980, 333-149981, 333-152171, 333-157376, 333-160969, 333-163479, 333-161442, 333-177506, 333-182330, 333-183037, 333-192748, 333-192749, 333-200452 and 333-200453) and Forms S-8 (Nos. 333-152168, 333-158260, 333-162955, 333-170044, 333-178158, 333-184004, 333-189611 and 333-196510).
Yours very truly,
/s/ Marcum LLP
Marcum LLP
San Francisco, California